← board
FENC
distress 2/10 · well-funded / low risk$10.14-2%today-9% from 52w high
Lead: cisplatin-induced ototoxicity
Revenue
$15M
Liquidity
$40M
Runway
7.0 yrs
Shares 1y
+25%
Price & events
+30.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-2.8%
1W
-1.5%
1M
+52.3%
3M
+32.4%
6M
+16.2%
1Y
+51.4%
2Y
+54.2%
5Y
+36.0%
All
Overview
- Market Cap
- $352.41M
- Enterprise Value
- $331.61M
- Volume
- 2.65K
- 52 Week Range
- $5.77 – $11.16
- Total Shares
- 34.74M
- Float Shares
- 16.83M
- Short %
- 1.63%
- % Held by Insiders
- 14.46%
- % Held by Institutions
- 54.29%
- RVOL
- 0.01x
- Beta
- 1.07
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026 ASCO Annual Meetingconferencedata presentationsecondaryPEDMARK · Presentation of four studies at ASCO 2026SEC 8-K
- 2026-03-16partnershipPEDMARK · License Agreement with Cipla resolving patent litigation, generic entry no earlier than September 1, 2033.SEC 8-K
- 2026-03-04partnershipPEDMARK (sodium thiosulfate injection) · Clinical research collaboration with Tampa General Hospital Cancer Institute.SEC 8-K
- expected to close on November 17, 2025enrollment completesecondaryClosing of underwritten public offering of common sharesSEC 8-K
- 2025-11-13partnershipPriced public offering of 4,666,667 common shares at $7.50 per share, expected gross proceeds ~$35M.SEC 8-K
- 2024-03-01partnershipPEDMARQSI · Exclusive licensing agreement with Norgine for EU, Australia, NZ.SEC 8-K
Approved drugs (1)
- PEDMARKSODIUM THIOSULFATE2022 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-22HC Wainwright & Co.Buy
- 2026-04-16WedbushOutperform
- 2026-01-09Piper SandlerOverweight
- 2025-08-21HC Wainwright & Co.Buy
- 2025-08-15Craig-HallumBuy
- 2025-05-20HC Wainwright & Co.Buy
Competitors — cisplatin-induced ototoxicity
- none identified
Recent news
- 2026-07-21What's Going On With Fennec Pharmaceuticals Inc Stock Tuesday? - Wealth Awesome
- 2026-07-20Why Fennec Pharmaceuticals Inc stock is sliding today - Wealth Awesome
- 2026-07-17Why Fennec Pharmaceuticals Inc stock is sliding today - Wealth Awesome
- 2026-07-13Why Fennec Pharmaceuticals Inc stock is rising today - Wealth Awesome
- 2026-07-13Understanding the Setup: (FENC) and Scalable Risk - Stock Traders Daily
- 2026-07-02Fennec (NASDAQ: FENC) ex-director exercises options, sells shares for taxes - Stock Titan
- 2026-07-01Fennec (NASDAQ: FENC) Chief Strategy Officer receives 156-share stock award - Stock Titan
- 2026-07-01Fennec (NASDAQ: FENC) CMO awarded 168 shares, holds 21,183 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.